divesiran

all catalysts(0)

nothing on the calendar yet

News(6)

• Disc sets up polycythemia vera challenge but Silence maintains lead
  The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…
  biospace · 22d ago
• Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
  Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…
  biopharma_dive · 1mo ago
• Silence causes uproar in rare blood cancer space as data sets high bar for competitors
  The mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…
  biospace · 1mo ago
• Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
  Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...
  endpoints · 1mo ago
• STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
  A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
  stat · 1mo ago
• Silence brings the noise to Takeda with phase 2 blood cancer win
  A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…
  fiercebiotech · 1mo ago